Intensive Care Medicine

, Volume 29, Issue 5, pp 691–698 | Cite as

The impact of critical care pharmacists on enhancing patient outcomes

  • Sandra L. Kane
  • Robert J. Weber
  • Joseph F. Dasta


The highly specialized knowledge and skills needed to care for critically ill patients requires a multidisciplinary team approach. Pharmacists are integral members of this team. They make valuable contributions to improve clinical, economic, and humanistic outcomes of patients. The purpose of this article is to review the literature pertaining to pharmacists' contributions within a multidisciplinary intensivist-led intensive care unit (ICU) team. Pharmacist interventions include correcting/clarifying orders, providing drug information, suggesting alternative therapies, identifying drug interactions, and therapeutic drug monitoring. Pharmacist involvement in improving clinical outcomes of critically ill patients is associated with optimal fluid management and substantial reductions in the rates of adverse drug events, medication administration errors, and ventilator-associated pneumonia. Furthermore, economic evaluations of clinical pharmacy services in the ICU consistently reveal the potential for considerable cost savings.


Critical care Pharmacy Outcomes Pharmacotherapy Cost-effectiveness Intensive care 


  1. 1.
    Ferdinande P (1997) Recommendation on minimal requirements for intensive care departments. Intensive Care Med 23:226–232PubMedGoogle Scholar
  2. 2.
    Pronovost PJ, Angus DC, Dorman T, Robinson KA, Dremsizov TT, Young TL (2002) Physician staffing patterns and clinical outcomes in critically ill patients: a systemic review. JAMA 288:2151–2162PubMedGoogle Scholar
  3. 3.
    Kaye J, Ashline V, Erickson D, Zeiler K, Gavigan D, Gannon L, Wynne P, Cooper J, Kittle W, Sharma K, Morton J (2000) Critical care bug team: a multi-disciplinary team approach to reducing ventilator-associated pneumonia. Am J Infection Control 28:197–201Google Scholar
  4. 4.
    Henneman E, Dracup K, Ganz T, Molayeme O, Cooper CB (2002) Using a collaborative weaning plan to decrease duration of mechanical ventilation and length of stay in the intensive care unit for patients receiving long-term ventilation. Am J Crit Care 11:132–140PubMedGoogle Scholar
  5. 5.
    Stenger K, Schooley K, Moss L (2001) Moving to evidence-based practice for pain management in the critical care setting. Crit Care Nurs Clin North Am 13:319–327PubMedGoogle Scholar
  6. 6.
    Bjornson DC, Hiner WO, Potyk RP, Nelson BA, Lombardo FA, Morton TA, Larson LV, Martin BP, Sikora RG, Cammarata FA (1993) Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharm 50:1875–1884PubMedGoogle Scholar
  7. 7.
    Devlin JW, Holbrook AM, Fuller HD (1997) The effect of ICU sedation guidelines and pharmacist interventions on clinical outcomes and drug cost. Ann Pharmacotherapy 31:689–695Google Scholar
  8. 8.
    Dasta JF (1996) Evolving role of the pharmacist in the critical care environment J Clin Anesth 8:99S-102SGoogle Scholar
  9. 9.
    Kilroy RA, Iafrate R (1993) Provision of pharmaceutical care in the intensive care unit. Crit Care Nurs Clinics North Am 5:221–225Google Scholar
  10. 10.
    Dasta JF, Segal R, Cunningham A (1989) National survey of critical-care pharmaceutical services. Am J Hosp Pharm 46:2308–2312PubMedGoogle Scholar
  11. 11.
    Hahn K, Marlowe K, Chicella M (2001) Survey of pharmaceutical services in pediatric resuscitation. Am J Hosp Pharm 58:1626–1628Google Scholar
  12. 12.
    Madhavan SS, Rosenbluth SA, Amonkar M, Borker RD, Richards T (2001) Pharmacists and immunizations: a national survey. J Am Pharm Assoc 41:32–45Google Scholar
  13. 13.
    Monaghan MJ, Monaghan MS (1998) Are pharmacists and pharmaceutical care having an impact on diabetes? Pharm Pract Manage Q 17:8–16Google Scholar
  14. 14.
    Pedersen CA, Schneider PJ, Santell JP, Kelly EJ (2000) ASHP national survey of pharmacy practice in acute care settings: monitoring, patient education and wellness-2000. Am J Health Sys Pharm 57:2171–2187Google Scholar
  15. 15.
    Rignold DJ, Santell JP, Schneider PJ (2000) ASHP national survey of pharmacy practice in acute care settings: dispensing and administration-1999. Am J Health Sys Pharm 57:1759–1775Google Scholar
  16. 16.
    Rudis MI, Brandl KM, SCCM/ACCP Task Force (2000) Position paper on critical care pharmacy services. Crit Care Med 28:3746–3750PubMedGoogle Scholar
  17. 17.
    Society of Critical Care Medicine and American College of Clinical Pharmacy (2000) Position paper on critical care pharmacy services. Pharmacotherapy 20:1400–1406PubMedGoogle Scholar
  18. 18.
    Hatoum HT, Hutchinson RA, Witte KW, Newby GY (1988) Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm 22:252–259PubMedGoogle Scholar
  19. 19.
    Bond CA, Raehl CL, Franke T (1999) Clinical pharmacy services and hospital mortality rates. Pharmacotherapy 19:556–564PubMedGoogle Scholar
  20. 20.
    Bond CA, Raehl CL, Franke T (2001) Interrelationships among mortality rates, drug costs, total cost of care and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy 21:129–141PubMedGoogle Scholar
  21. 21.
    Rubenfeld GD, Angus DC, Pinsky J (1999) Outcomes research in critical care. Am J Respir Crit Care Med 160:358–367PubMedGoogle Scholar
  22. 22.
    Kozma CM, Reeder CE, Schulz RM (1993) Economic, clinical and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther 15:1121–1132PubMedGoogle Scholar
  23. 23.
    Calabrese AD, Erstad BL, Brandl K, Barletta J, Kane SL, Sherman DS (2001) Medication administration errors in adult patients in the ICU. Intensive Care Med 27:1592–1598PubMedGoogle Scholar
  24. 24.
    Rudis MI, Sikora CA, Angus E, Peterson E, Popovich J, Hyzy R, Zarowitz BJ (1997) A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 25:575–583Google Scholar
  25. 25.
    Lavny S, Hammerman A, Shani S, Shemer J (2000) Israel hospital pharmaceutical services: a national survey. Harefuah 138:828–831PubMedGoogle Scholar
  26. 26.
    Cotter SM, Barber ND, McKee M (1994) Survey of clinical pharmacy services in United Kingdom National Health Service hospitals. Am J Hosp Pharm 51:2676–2684PubMedGoogle Scholar
  27. 27.
    Boyko WL, Yurkowski PJ, Ivey MF, Marianne F. Ivey, Armitstead JA, Roberts BL (1997) Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health-Syst Pharm 54:1591–1595Google Scholar
  28. 28.
    Broyles JE, Brown RO, Vehe KL, Nolly RJ, Luther W (1991) Pharmacist interventions impove fluid balance in fluid-restricted patients requiring parenteral nutrition. DICP 25:119–122PubMedGoogle Scholar
  29. 29.
    Hatton J (1992) Multidisciplinary drug-use for stress ulcer prophylaxis. Am J Hosp Pharm 49:1440–1444PubMedGoogle Scholar
  30. 30.
    Tierney M, Carter-Snell C, Cardinal P, Baxter A (1996) Comparison of duration of mechanical ventilation and cost associated with midazolam and lorazepam infusions in critically ill patients. Can J Hosp Pharm 49:211–215Google Scholar
  31. 31.
    Hadbavny AM, Hoyt JW (1993) Promotion of cost-effective benzodiazepine sedation. Am J Hosp Pharm 50:60–61Google Scholar
  32. 32.
    Kane SL, Gerlach AT, Cook CH, Essig G, Dasta JF (2001) Variation of bispectral index (BIS) values in chemically paralyzed patients. Pharmacotherapy 21:369Google Scholar
  33. 33.
    Zarowitz BJ, Rudis MI, Lai K, Petitta A, Lulek M (1997) Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients. Pharmacotherapy 17:327–332PubMedGoogle Scholar
  34. 34.
    Rudis MI, Guslits BJ, Peterson EL, Hathaway SJ, Angus E, Beis S, Zarowitz BJ (1996) Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 24:1749–1756PubMedGoogle Scholar
  35. 35.
    Dager WE, Alberson TE (1992) Impact of therapeutic drug monitoring of intravenous theophylline regimens on serum theophylline concentrations in the medical intensive care unit. Ann Pharmacotherapy 26:1287–1291Google Scholar
  36. 36.
    Streetman DS, Nafziger AN, Destache CJ, Bertino JS (2001) Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy 21:443–451PubMedGoogle Scholar
  37. 37.
    Leape LL, Cullen DJ, Dempsey Clapp M, Burdick M, Demonaco HJ, Erickson JI, Bates DW (1999) Pharmacist participation on physician rounds and adverse events in the intensive care unit. JAMA 282:267–270PubMedGoogle Scholar
  38. 38.
    Tissot E, Cornette C, Demoly P, Jacquet M, Barale F, Capellier G (1999) Medication errors at the administration phase in an intensive care unit. Intensive Care Med 25:353–359PubMedGoogle Scholar
  39. 39.
    Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections. Chest 115:462–474PubMedGoogle Scholar
  40. 40.
    Klem C, Dasta JF (1996) Efforts of pharmacy to reduce antibiotic resistance. New Horiz 4:377–384PubMedGoogle Scholar
  41. 41.
    Ibrahim KH, Gunderson B, Rotschafer JC (2001) Intensive care unit antimicrobial resistance and the role of the pharmacist. Crit Care Med 29 [Suppl]:N108-N113Google Scholar
  42. 42.
    Weber RJ, Kane SL, Oriolo VA, Saul M, Skledar SJ, Dasta JF (2003) The impact of ICU drug use on hospital costs: a descriptive analysis with recommendations for optimizing ICU pharmacotherapy. Crit Care Med 31:s17-s24PubMedGoogle Scholar
  43. 43.
    Sznajder M, Aegerter M, Launois Merliere Y, Guidet B, CubRea (2001) A cost-effectiveness analysis of stays in intensive care units. Intensive Care Med 27:146–153PubMedGoogle Scholar
  44. 44.
    Chaung LC, Sutton JD, Henderson GT (1994) Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit. Hosp Pharm 29:215–218PubMedGoogle Scholar
  45. 45.
    Singer M, Myers S, Hall G, Cohen SL, Armstrong RF (1994) The cost of intensive care: a comparison on one unit between 1988 and 1991. Intensive Care Med 20:542–549PubMedGoogle Scholar
  46. 46.
    Schmock GT, Meek PD, Ploetz PA, Vermeulen LC (1996) Economic evaluations of clinical pharmacy services-1988–1995. Pharmacotherapy 16:1188–1208Google Scholar
  47. 47.
    Baldinger SL, Chow MSS, Gannon RH, Kelly ET (1997) Cost savings from having a clinical pharmacist work part-time in a medical intensive care unit. Am J Health-Syst Pharm 54:2811–2814Google Scholar
  48. 48.
    Krupicka MI, Bratton SL, Sonnenthal K, Goldstein B (2002) Impact of a pediatric clinical pharmacist in the pediatric intensive care unit. Crit Care Med 30:919–921PubMedGoogle Scholar
  49. 49.
    Montazeri M, Cook DJ (1994) Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med 22:1044–1048PubMedGoogle Scholar
  50. 50.
    Miyagawa CI, Rivera JO (1986) Effect of pharmacist interventions on drug therapy costs in surgical intensive-care unit. Am J Hosp Pharm 43:3008–3013PubMedGoogle Scholar
  51. 51.
    White CM, Chow MSS (1998) Cost impact and clinical benefits of focused rounding in the cardiovascular intensive care unit. Hosp Pharm 33:419–423Google Scholar
  52. 52.
    Hurel D, Loirat P, Saulnier E, Nicolas F, Brivet F (1997) Quality of life 6 months after intensive care: results of a prospective multi-center study using a generic health status scale and satisfaction scale. Intensive Care Med 23:331–337CrossRefGoogle Scholar
  53. 53.
    Schelling G, Stoll C, Haller M, Briegel J, Manert W, Hummel T, Lenhart A, Heyduck M, Polasek J, Meier M, Preuss U, Bullinger M, Schuffel W, Peter K (1998) Health-related quality of life and posttramatic stress disorder in survivors of the acute respiratory distress syndrome. Crit Care Med 26:651–659Google Scholar
  54. 54.
    Badia X, Diaz-Prieto A, Rue M, Patrick DL (1996) Measuring health and health state preferences among critically ill patients. Intensive Care Med 22:1379–1384CrossRefGoogle Scholar
  55. 55.
    Chrispin PS, Scotton H, Lloyd RD, Lloyd D, Ridley SA (1997) Short form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire. Anaesthesia 52:15–23PubMedGoogle Scholar
  56. 56.
    Pickard AS, Johnson JA, Farris KB (1999) The impact of pharmacist interventions on health-related quality of life. Ann Pharmacotherapy 33:1167–1172Google Scholar
  57. 57.
    Bungay KM (2000) Methods to assess the humanistic outcomes of clinical pharmacy services. Pharmacotherapy 20:253S-258SPubMedGoogle Scholar
  58. 58.
    Devlin JW, Boleski G, Mlynarek M, Nerenx DR, Peterson E, Jankowski M, Horst HM, Zarowitz BJ (1999) Motor activity assessment scale: a valid and reliable sedation scale for use with mechanically ventilated patients in a surgical intensive care unit. Crit Care Med 27:1271–1275Google Scholar
  59. 59.
    Nelson BJ, Weinert CR, Bury CL, Marinelli WA, Gross CR (2000) Intensive care unit drug use and subsequent quality of life in acute lung injury patients. Crit Care Med 28:3626–3630Google Scholar
  60. 60.
    Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL (1997) Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general units. Crit Care Med 25:1289–1297Google Scholar
  61. 61.
    Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients. JAMA 279:1200–1205PubMedGoogle Scholar
  62. 62.
    Stratton TP, Wu B, Nakagawa RS (1993) Obtaining a critical care pharmacist position: a marketing case study. Can J Hosp Pharm 46:109–114PubMedGoogle Scholar
  63. 63.
    Katona BG, Ayd PR, Walters JK, Caspi M, Finkelstein BW (1989) Effect of a pharmacist's and a nurse's interventions on cost of drug therapy in a medical intensive-care unit. Am J Hosp Pharm 46:1179–1182PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Sandra L. Kane
    • 1
  • Robert J. Weber
    • 1
  • Joseph F. Dasta
    • 2
  1. 1.School of PharmacyUniversity of PittsburghPittsburghUSA
  2. 2.College of PharmacyThe Ohio State UniversityColumbusUSA

Personalised recommendations